Characteristics | Local consolidation RT (n=26) | Observation (n = 22) | P value |
Age (years) |
|
|
|
˂60 | 16 (61.5%) | 12 (54.5%) | 0.77 |
≥60 | 10 (38.5%) | 10 (45.5%) | |
Sex |
|
|
|
Male | 16 (61.5%) | 17 (77.3%) | 0.35 |
Female | 10 (38.5%) | 5 (22.7%) | |
ECOG performance status |
|
|
|
0 - 1 | 17 (65.4%) | 12 (54.5%) | 0.56 |
2 | 9 (34.6%) | 10 (45.5%) | |
Pathology |
|
|
|
Squamous cell carcinoma | 10 (38.4%) | 8 (36.4%) | 0.46 |
Adenocarcinoma | 9 (34.6%) | 9 (40.9%) | |
others | 7 (27%) | 5 (22.7%) | |
T stage |
|
|
|
T1/T2 | 13 (50%) | 7 (31.8%) | 0.25 |
T3/T4 | 13 (50%) | 15 (68.2%) | |
N stage |
|
|
|
N0/N1 | 14 (53.8%) | 14 (63.6%) | 0.57 |
N2/N3 | 12 (46.2%) | 8 (36.4%) | |
Response to Treatment |
|
|
|
Partial | 13 (50%) | 7 (31.8%) | 0.25 |
Stationary | 13 (50%) | 15 (68.2%) | |
Number of metastasis |
|
|
|
1 - 3 | 21 (80.8%) | 12 (54.5%) | 0.07 |
4 - 5 | 5 (19.2%) | 10 (45.5%) | |
EGFR |
|
|
|
Negative | 8 (30.8%) | 7 (31.8%) | 0.96 |
Positive | 3 (11.5%) | 2 (9.1%) | |
Not applicable | 15 (57.7%) | 13 (59.1%) | |
ALK |
|
|
|
Negative | 11 (42.3%) | 8 (36.4%) | 0.52 |
Positive | 0 (0%) | 1 (4.5%) | |
Not applicable | 15 (57.7%) | 13 (59.1%) | |
CNS metastasis |
|
|
|
Yes | 5 (19.2%) | 6 (27.3%) | 0.73 |
No | 21 (80.8%) | 16 (72.7%) | |
Site of metastasis |
|
|
|
Single organ | 14 (53.8%) | 6 (27.3%) | 0.06 |
Multiple organ | 12 (46.2%) | 16 (72.7%) |